(4S,5S)-4-异丁基-5-(2-羟乙基)恶唑烷-2-酮 | 109864-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4S,5S)-4-异丁基-5-(2-羟乙基)恶唑烷-2-酮
• 英文名称: (4S,5S)-4-isobutyl-5-(2-hydroxyethyl)oxazolidin-2-one
• 英文别名: (4S,5S)-5-(2-hydroxyethyl)-4-isobutyl-2-oxazolidinone；4(S)-isobutyl-5(S)-(2-hydroxyethyl)-2-oxazolidinone；(4S,5S)-5-(2-hydroxyethyl)-4-(2-methylpropyl)-1,3-oxazolidin-2-one
• CAS: 109864-65-5
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: KBMPQXLLTVMXKB-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,5S)-4-异丁基-5-(2-羟乙基)恶唑烷-2-酮 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 4(S)-Isobutyl-5(S)-[2-(isobutylmercapto)ethyl]-2-oxazolidinone
  参考文献：
  名称：

  Renin inhibitors. Dipeptide analogs of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond

  摘要：

  A series of dipeptide analogues of angiotensinogen have been prepared and evaluated for their ability to inhibit the aspartic proteinase renin. The compounds were derived from the renin substrate by replacing the scissile amide bond with a transition-state mimic and by incorporating bioisosteric replacements for the Val-10 amide bond. Analogue 21a exhibited an IC50 of 7.6 nM against purified human renin, showed high specificity for this enzyme, and produced a hypotensive response in anesthetized, salt-depleted cynomolgus monkeys.

  DOI：

  10.1021/jm00393a008
• 作为产物：
  描述：

  N-叔丁氧羰基-L-亮氨醇 在 2,6-二甲基吡啶 、 sodium hydroxide 、 N-氯代丁二酰亚胺 、 9-borabicyclo[3.3.1]nonane dimer 、 pyridine-SO3 complex 、 三氟化硼乙醚 、 双氧水 、 silver fluoride 、 二异丁基氢化铝 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 68.5h， 生成 (4S,5S)-4-异丁基-5-(2-羟乙基)恶唑烷-2-酮
  参考文献：
  名称：

  通过氨基甲酸叔丁基二甲基硅烷基酯形成环状氨基甲酸酯的新模式。他汀类药物及其类似物的立体选择性合成

  摘要：

  使用S N 2'（由AgF或AgF-Pd（II）引发）由叔丁基二甲基甲硅烷基氨基甲酸酯形成的环状氨基甲酸酯，进行1,2-和1,3-氨基羟基系统的立体选择性构建。该方法有效地应用于了他汀类药物和AHPPA的合成。

  DOI：

  10.1016/s0040-4039(00)96439-6

文献信息

• Synthesis of (3<i>S</i>,4<i>S</i>)-Statine and a Related Compound, (3<i>S</i>,4<i>S</i>)-AHPPA, from D-Glucosamine as a Chiral Pool
  作者：Katsuo Shinozaki、Kazuhiro Mizuno、Hirohisa Oda、Yukio Masaki

  DOI：10.1246/bcsj.69.1737

  日期：1996.6

  4S)-statine ((3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid) (1) and (3S,4S)-AHPPA (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid) (2), were synthesized starting from D-glucosamine (3) as a chiral pool. Two routes for the transformation of D-glucosamine to key intermediates, which are applicable to the synthesis of threo-β-hydroxy-γ-amino acids, were investigated. The successful route involved

  生物学上重要的苏-β-羟基-γ-氨基酸，(3S,4S)-statine ((3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid) (1) 和 (3S,4S)- AHPPA (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid) (2) 从 D-葡糖胺 (3) 开始合成为手性池。研究了将 D-氨基葡萄糖转化为关键中间体的两条路线，适用于合成苏式-β-羟基-γ-氨基酸。成功的路线包括 C(6)-碳降解和 D-葡糖胺的 C(4)-羟基的消除，分 8 步，总产率为 30%，以提供 (4R,5S)-2-oxo-5-vinyloxazolidine- 4-甲醛二甲基乙缩醛 (17)，已被用作合成目标化合物的通用中间体。
• Angiotensinogen analogs
  申请人：Abbott Laboratories

  公开号：US04857507A1

  公开（公告）日：1989-08-15

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen, R.sub.3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R.sub.5 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.2 and R.sub.4 are independently selected from hydrogen and loweralkyl; R.sub.6 is CHOH or CO; R.sub.7 is CH.sub.2, CF.sub.2 or CF with the proviso that when R.sub.6 is CO, R.sub.7 is CF.sub.2 ; R.sub.8 is CH.sub.2, CHR.sub.14 wherein R.sub.14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R.sub.7 and R.sub.8 taken together can be ##STR3## with the proviso that when R.sub.7 is CF.sub.2, R.sub.8 is CH.sub.2 ; E is O, S, SO, SO.sub.2, NR.sub.15 wherein R.sub.15 is hydrogen or loweralkyl or NR.sub.16 CO wherein R.sub.16 is hydrogen or loweralkyl; R.sub.9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R.sub.9 taken together can be N.sub.3, with the proviso that when E is NH, R.sub.9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。
• Enantiospecific Synthesis of (3<i>S</i>, 4<i>S</i>)-Statine and Its Analogue from D-Glucosamine as a Chiral Pool
  作者：Katsuo Shinozaki、Kazuhiro Mizuno、Hirohisa Oda、Yukio Masaki

  DOI：10.1246/cl.1992.2265

  日期：1992.12

  The C(6)-carbon degradation and elimination of C(4)-hydroxy group of D-glucosamine were achieved in 8-steps and 30% overall yield to furnish (4R, 5S)-5-vinyl-2-oxazolidinone-4-carbaldehyde dimethyl acetal, which was utilized as a key intermediate for enantiospecific synthesis of biologically important threo β-hydroxy-γ-amino acids, natural (3S, 4S)-statine and (3S, 4S)-AHPPA

  D-氨基葡萄糖的 C(6)-碳降解和 C(4)-羟基的消除分 8 步实现，总产率为 30%，得到 (4R, 5S)-5-vinyl-2-oxazolidinone-4 -甲醛二甲基乙缩醛，用作对映特异性合成具有生物学重要意义的苏式 β-羟基-γ-氨基酸、天然 (3S, 4S)-statine 和 (3S, 4S)-AHPPA 的关键中间体
• The Lewis acid mediated reaction of carbamates with γ-oxygenated allyltin and its application to (±)-statine synthesis
  作者：Yoshinori Yamamoto、Martin Schmid

  DOI：10.1039/c39890001310

  日期：——

  The Lewis acid mediated reaction of acyliminium ions (6) with γ-oxygen substituted allyltin (1c) gave the amino alcohol derivatives (7) and/or (8) in good yields; in certain cases very high diastereoselectivity was achieved and the procedure was applied to the synthesis of (±)-statine.

  路易斯酸介导的丙烯酰亚胺离子（6）与γ-氧取代的烯丙基锡（1c）的反应以良好的收率得到了氨基醇衍生物（7）和/或（8）。在某些情况下，获得了很高的非对映选择性，并将该方法应用于（±）-他汀类药物的合成。
• Retroviral protease inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0342541A2

  公开（公告）日：1989-11-23

  A retroviral protease inhibiting compound of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof.

  一种抑制逆转录病毒蛋白酶的式化合物： 或其药学上可接受的盐、原药或酯。